ROLE OF CYTOCHROMES P450 IN DRUG-METABOLISM AND HEPATOTOXICITY

被引:158
作者
WATKINS, PB
机构
关键词
D O I
10.1055/s-2008-1040480
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The cytochromes P450 may represent the major metabolic frontier between the environment and the body. The recent discovery of interpatient differences in P450 profile has provided a plausible explantation for heterogeneous dosing requirements for some individual drugs. The heterogeneity in P450 profiles appears to also account for some ''idiosyncratic'' drug reactions, especially hepatotoxicity. An important challenge for the future is the development of safe and noninvasive tests capable of determining patients' P450 profiles. It is likely that such tests will greatly facilitate individualization of dosing of many drugs in the future. In addition, such tests should be useful in identifying patients likely to develop ''idiosyncratic'' toxicity to specific drugs. Finally, it seems likely that interpatient differences in P450 profile may at least in part explain interpatient differences in susceptibility to environmental diseases. For example, it may in the future be possible to identify individuals with P450 profiels that render them susceptible to leukemia from xenobiotics such as benzene. Such individuals could be advised not to work in an environment containing these chemicals or, alternatively, to take a medication which reduces their risk by appropriately altering their P450 profile. Identification and in vitro characterization of human P450s is now well underway and may be largely completed within the next decade. However, studies addressing the clinical significance of interpatient differences in P450 profile, as well as the genetic and nongenetic factors that underlie this heterogeneity, are just beginning. This should remain a rewarding area of research for many years to come.
引用
收藏
页码:235 / 250
页数:16
相关论文
共 176 条
[41]   THE INCREASE IN URINARY-EXCRETION OF 6-BETA-HYDROXYCORTISOL AS A MARKER OF HUMAN HEPATIC CYTOCHROME-P450IIIA INDUCTION [J].
GED, C ;
ROUILLON, JM ;
PICHARD, L ;
COMBALBERT, J ;
BRESSOT, N ;
BORIES, P ;
MICHEL, H ;
BEAUNE, P ;
MAUREL, P .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 (04) :373-387
[42]   HUMAN P450PCN1 - SEQUENCE, CHROMOSOME LOCALIZATION, AND DIRECT EVIDENCE THROUGH CDNA EXPRESSION THAT P450PCN1 IS NIFEDIPINE OXIDASE [J].
GONZALEZ, FJ ;
SCHMID, BJ ;
UMENO, M ;
MCBRIDE, OW ;
HARDWICK, JP ;
MEYER, UA ;
GELBOIN, HV ;
IDLE, JR .
DNA-A JOURNAL OF MOLECULAR & CELLULAR BIOLOGY, 1988, 7 (02) :79-86
[43]   CHARACTERIZATION OF THE COMMON GENETIC-DEFECT IN HUMANS DEFICIENT IN DEBRISOQUINE METABOLISM [J].
GONZALEZ, FJ ;
SKODA, RC ;
KIMURA, S ;
UMENO, M ;
ZANGER, UM ;
NEBERT, DW ;
GELBOIN, HV ;
HARDWICK, JP ;
MEYER, UA .
NATURE, 1988, 331 (6155) :442-446
[44]   MOLECULAR-GENETICS OF THE P-450 SUPERFAMILY [J].
GONZALEZ, FJ .
PHARMACOLOGY & THERAPEUTICS, 1990, 45 (01) :1-38
[45]   P450-GENES - EVOLUTION, REGULATION, AND RELATIONSHIP TO HUMAN CANCER AND PHARMACOGENETICS [J].
GONZALEZ, FJ ;
JAISWAL, AK ;
NEBERT, DW .
COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, 1986, 51 :879-890
[46]  
GUENGERICH FP, 1986, J BIOL CHEM, V261, P5051
[47]  
GUENGERICH FP, 1989, ANNU REV PHARMACOL, V29, P241
[48]   PURIFICATION AND CHARACTERIZATION OF LIVER MICROSOMAL CYTOCHROMES-P-450 - ELECTROPHORETIC, SPECTRAL, CATALYTIC, AND IMMUNOCHEMICAL PROPERTIES AND INDUCIBILITY OF 8 ISOZYMES ISOLATED FROM RATS TREATED WITH PHENOBARBITAL OR BETA-NAPHTHOFLAVONE [J].
GUENGERICH, FP ;
DANNAN, GA ;
WRIGHT, ST ;
MARTIN, MV ;
KAMINSKY, LS .
BIOCHEMISTRY, 1982, 21 (23) :6019-6030
[49]  
GUENGERICH FP, 1986, MOL PHARMACOL, V30, P287
[50]   CYCLOSPORIN-ERYTHROMYCIN INTERACTION IN RENAL-TRANSPLANT PATIENTS [J].
GUPTA, SK ;
BAKRAN, A ;
JOHNSON, RWG ;
ROWLAND, M .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 27 (04) :475-481